American Society of Clinical Oncology (ASCO)
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
* PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor response with clinically meaningful improvements in certain clinical outcome assessments, including physical function ...
NEC Returns to Singapore Fintech Festival with AI-Powered Financial Services Solutions
SINGAPORE, Nov. 10, 2026 /PRNewswire/ -- NEC Asia Pacific will return to the
SingaporeFinTech Festival (SFF), taking place from 18 to 20 November 2026 at
Singapore EXPO.
TPEx Successfully Concludes 2026 Forum on Building New Core of Asian Bond Markets
TAIPEI, Nov. 6, 2026 /PRNewswire/ -- The Taipei Exchange (TPEx) hosted the 2026 Taiwan Week Forum, "Building a New Core of Asian Bond Market," on November 5. Focusing on expanding Taiwan's bond market, strengthening international linkages, and advancing sustainable and transition finance, the for...
NCCN and Viet Nam National Cancer Hospital Expand Collaboration to Advance Cancer Care Resources in Vietnam
NCCN and Viet Nam National Cancer Hospital sign agreement to enhance ongoing guideline adaptation efforts with the inclusion of additional hematologic and solid tumor information. HANOI, Vietnam, Nov. 5, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the...
PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium
Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-targeted therapy BURLINGTON, Mass., Nov. 3, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage biotechnology company developing tar...
Laboratoires Pierre Fabre announces the approval of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer with a BRAFV600E mutation in Singapore
* New targeted treatment option now available in for adult patients with BRAF V600E mutant advanced non-small cell lung cancer (NSCLC) * Launch follows European approval based on results from the Phase II PHAROS trial, demonstrating meaningful clinical benefit to patients with a high objective...
Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial
Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease TAMPA, Florida, Nov. 2, 2026 /PRNewswire/ -- Sirolimus-coated balloon (SCB) strategy was non-inferior to con...
Insira Launches as Independent Company Built on Cortellis and DRG
Company builds on industry-leading life sciences data and expertise to support
the success of treatment innovation.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Insira
Fox ESS Builds on Residential Success with Expanded C&I Solutions at All Energy Australia 2026
MELBOURNE, Australia, Oct. 29, 2026 /PRNewswire/ -- Fox ESS (Fox) showcases Power Beast, G-Max Plus, Power Cube, AirGate and FoxCloud 2.0 at Booth N123, All Energy Australia on 28–29 October. Fox brand ambassador, Australian swimming legend Ian Thorpe joined mascot Maimai in welcoming guests. ...
Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology
CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis o...
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
* The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings. SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PR...
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
* PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two groups, respectively. * Responses were more dur...
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis - Pivotal trial designed to enroll approxima...
ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026
SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011,will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These p...
TraceLink Unveils Chorus to Integrate-Once™ Across Enterprise and Internet Data Sources with MCP or API Access
Chorus extends the OPUS Agentic Supply Chain Operating System with governed, real-time access to enterprise and internet data, enabling humans and OPUS Agents to work with information and take approved actions while records remain in their authoritative source systems BOSTON, Oct. 22, 2026 /PRNe...
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
* Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines * Appointments support continued advancement of Everest's mRNA pip...
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
* Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) * New research across clinical trial endpoints, biomarkers, diagnostic t...
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific...
STARTRADER Named Best Fintech Forex Broker at Forex Expo Dubai 2026
The award, presented at the ninth edition of the region's leading trading gathering, caps a year of continuous product expansion. DUBAI, UAE, Sept. 24, 2026 /PRNewswire/ -- STARTRADER was named Best Fintech Forex Broker at the Forex Expo Dubai Awards, organised by HQMENA and presented during For...
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
